keyword
MENU ▼
Read by QxMD icon Read
search

Adjuvant chemotherapy and breast cancer

keyword
https://www.readbyqxmd.com/read/28332699/mitotic-index-matter-how-to-improve-the-assessment-of-mitosis-in-order-to-better-classify-g2-breast-cancer-and-luminal-a-category
#1
Rachele Del Sordo, Guido Bellezza, Ivana Ferri, Anjuta Pireddu, Renato Colella, Angelo Sidoni
G2 ductal infiltrating carcinomas are a heterogeneous group of tumours with ambiguous clinical significance. This is because G2 carcinomas are almost always the largest category and poorly reproducible. Mitotic count (MC) is one of the causes of poor histological grading reproducibility. The phosphoistone H3 (PPH3) antibody improves identification of mitotic figures. The aim of our study is to demonstrate whether using a new histological grading system based on PPH3 immunostaining to assess MC can re-stratify G2 category...
March 23, 2017: Histology and Histopathology
https://www.readbyqxmd.com/read/28331237/restricted-axillary-staging-in-clinically-and-sonographically-node-negative-early-invasive-breast-cancer-c-it1-2-in-the-context-of-breast-conserving-therapy-first-results-following-commencement-of-the-intergroup-sentinel-mamma-insema-trial
#2
T Reimer, A Stachs, V Nekljudova, S Loibl, S Hartmann, K Wolter, G Hildebrandt, B Gerber
Axillary lymph node status remains an important prognostic factor in early breast cancer. It is regarded as an indicator for (neo)adjuvant systemic treatment and postoperative radiotherapy of the regional lymphatics. Commenced in September 2015, the INSEMA trial is investigating whether operative determination of nodal status as part of breast conserving therapy (BCT) for early stage breast cancer (c/iT1-2 c/iN0) can be avoided without reducing oncological safety. After inclusion of 1001 patients there was general acceptance of the complex study design by patients and study doctors so that recruitment for the first randomisation (axillary sentinel lymph node biopsy [SLNB]: yes or no) achieved predicted case numbers...
February 2017: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/28327626/altered-resting-state-hippocampal-functional-networks-associated-with-chemotherapy-induced-prospective-memory-impairment-in-breast-cancer-survivors
#3
Huaidong Cheng, Wen Li, Liang Gong, Han Xuan, Zhonglian Huang, Hong Zhao, Long Sheng Wang, Kai Wang
In this study, we aimed to investigate the intrinsic hippocampal functional connectivity (FC) network and its relationship with prospective memory in patients with breast cancer suffering from chemotherapy-induced cognitive impairment (CICI). Thirty-four breast cancer patients before and after adjuvant chemotherapy (CB and CC, respectively) and 31 age- and education-matched cognitively normal (CN) women were recruited and subjected to a prospective memory task and a resting-state functional magnetic resonance imaging scan...
March 22, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28324267/chemotherapy-induced-irreversible-alopecia-in-early-breast-cancer-patients
#4
Gun Min Kim, Sanghwa Kim, Hyung Seok Park, Jee Ye Kim, Sanggen Nam, Seho Park, Seung Il Kim, DoYoung Kim, Joohyuk Sohn
PURPOSE: The purpose of this work is to determine the prevalence of chemotherapy-induced irreversible alopecia (CIIA), which is defined as an alopecia that exists at least 6 months after completion of chemotherapy and factors affecting CIIA in early breast cancer patients. METHODS: We performed a cross-sectional study. We retrospectively identified breast cancer patients who had received AC (Adriamycin, Cyclophosphamide) or AC-T (AC followed by Taxane) as neoadjuvant or adjuvant chemotherapy...
March 21, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28323331/survival-benefit-needed-to-undergo-chemotherapy-patient-and-physician-preferences
#5
Ines Vaz-Luis, Anne O'Neill, Karen Sepucha, Kathy D Miller, Emily Baker, Chau T Dang, Donald W Northfelt, Eric P Winer, George W Sledge, Bryan Schneider, Ann H Partridge
BACKGROUND: Published studies have suggested that most patients with early stage breast cancer are willing, for modest survival benefits, to receive 6 months of adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil, an older regimen that is used infrequently today. We examined preferences regarding the survival benefit needed to justify 6 months of a contemporary chemotherapy regimen. METHODS: The Eastern Cooperative Oncology Group Protocol 5103 was a phase 3 trial that randomized breast cancer patients to receive standard adjuvant doxorubicin, cyclophosphamide, and paclitaxel with either bevacizumab or placebo...
March 21, 2017: Cancer
https://www.readbyqxmd.com/read/28319455/joint-model-imputation-to-estimate-the-treatment-effect-on-long-term-survival-using-auxiliary-events
#6
Audrey Mauguen, Stefan Michiels, Virginie Rondeau
Clinical trial duration may be a concern in clinical research, especially in cancer trials where the endpoint is overall survival. A surrogate endpoint can be used as an auxiliary variable to analyze the treatment effect earlier. At an early time point, the high number of censored observations can be compensated by the imputation of the unobserved deaths times. We propose to use predictions of the risk of death from a joint model for a recurrent event and a terminal event, which account for disease relapse information...
February 16, 2017: Journal of Biopharmaceutical Statistics
https://www.readbyqxmd.com/read/28301555/risk-factors-for-delay-of-adjuvant-chemotherapy-in-non-metastatic-breast-cancer-patients-a-systematic-review-and-meta-analysis-involving-186982-patients
#7
Xiaofang He, Fen Ye, Bingcheng Zhao, Hailin Tang, Jin Wang, Xiangsheng Xiao, Xiaoming Xie
PURPOSE: Delay performance of adjuvant chemotherapy (AC) after surgery has been presented to affect survival of breast cancer patients adversely, but the risk factors for delay in initiation remain controversial. Therefore, we conducted this systematic review of the literature and meta-analysis aiming at identifying the risk factors for delay of adjuvant chemotherapy (DAC) in non-metastatic breast cancer patients. METHODS: The search was performed on PubMed, Embase, Chinese National Knowledge Infrastructure and Wanfang Database from inception up to July 2016...
2017: PloS One
https://www.readbyqxmd.com/read/28293118/cyp2d6-polymorphisms-may-predict-occurrence-of-adverse-effects-to-tamoxifen-a-preliminary-retrospective-study
#8
Ishani Wickramage, Kamani Hemamala Tennekoon, Merenchi Arachchige Yasantha Ariyaratne, Asanka Sudeshini Hewage, Tharmini Sundralingam
INTRODUCTION AND AIMS: Tamoxifen is an adjuvant drug effective in treating hormone receptor - positive breast cancer. However, 30%-50% of patients relapse and many develop adverse effects, such as hot flashes and fatty liver. Allelic variations altering the activity of cytochrome P450-2D6 enzyme affect response to tamoxifen by modulating metabolism of tamoxifen into its pharmacologically active metabolite endoxifen. Although association between CYP2D6 polymorphisms and recurrence of breast cancer in patients on tamoxifen had been reported, little evidence exists on association between these polymorphisms and adverse effects to tamoxifen...
2017: Breast Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/28288389/ovarian-ablation-for-premenopausal-breast-cancer-a-review-of-treatment-considerations-and-the-impact-of-premature-menopause
#9
REVIEW
Melica Nourmoussavi, Gary Pansegrau, Jason Popesku, Geoffrey L Hammond, Janice S Kwon, Mark S Carey
Historically, ovarian ablation (OA) was used as therapy for women with recurrent hormone-receptor-positive (HRP) premenopausal breast cancer. With the publication of the SOFT (Suppression of Ovarian Function Trial) and TEXT (Tamoxifen and Exemestane Trial) randomized trials, there is considerable interest in OA as an adjuvant treatment, either in combination with tamoxifen or an aromatase inhibitor (AI). Thus, we have reviewed current guidelines and key studies on this important topic and have highlighted the relevant biological and pharmacological aspects of the various endocrine therapies...
February 22, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28284826/permanent-alopecia-in-patients-with-breast-cancer-after-taxane-chemotherapy-and-adjuvant-hormonal-therapy-clinicopathologic-findings-in-a-cohort-of-10-patients
#10
Athina Fonia, Carlo Cota, Jane F Setterfield, Lynne J Goldberg, David A Fenton, Catherine M Stefanato
BACKGROUND: Anagen effluvium with reversible scalp alopecia is a known side effect of chemotherapy. However, there are an increasing number of reports in the literature documenting permanent alopecia in patients treated with taxanes. OBJECTIVE: We sought to describe the clinicopathologic features in breast cancer patients who underwent treatment with taxanes and adjuvant hormonal chemotherapy. METHODS: We reviewed the clinical and histopathologic information of a cohort of 10 patients treated with taxanes and adjuvant hormonal chemotherapy...
March 8, 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28282999/critical-decision-making-in-radiotherapy-for-early-stage-breast-cancer-in-a-neo-adjuvant-treatment-era
#11
Francesca De Felice, Mattia Falchetto Osti, Vitaliana De Sanctis, Daniela Musio, Vincenzo Tombolini
Introduction In breast cancer management, the role of adjuvant radiation therapy (RT) has been the subject of intense controversy over the past several years, due to the improvement in neoadjuvant chemotherapy (NACT) prescription. One of the most controversial questions regarding indication for adjuvant RT is whether or not RT is essential in patients with early stage disease at diagnosis. The value of adjuvant RT remains highly debatable in those patients with clinically negative nodes at the completion of NACT...
March 10, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28279941/long-term-outcome-of-the-remagus-02-trial-a-multicenter-randomised-phase-ii-trial-in-locally-advanced-breast-cancer%C3%A2-patients-treated-with-neoadjuvant-chemotherapy-with-or-without-celecoxib-or-trastuzumab-according-to-her2-status
#12
Sylvie Giacchetti, Anne-Sophie Hamy, Suzette Delaloge, Etienne Brain, Frédérique Berger, Brigitte Sigal-Zafrani, Marie-Christine Mathieu, Philippe Bertheau, Jean Marc Guinebretière, Mahasti Saghatchian, Florence Lerebours, Chafouny Mazouni, Olivier Tembo, Marc Espié, Fabien Reyal, Michel Marty, Bernard Asselain, Jean-Yves Pierga
BACKGROUND: The REMAGUS-02 multicenter randomised phase II trial showed that the addition to neoadjuvant chemotherapy (NAC) of trastuzumab in patients with localised HER2-positive breast cancer (BC) increased the pathological complete response (pCR) rate and that the addition of celecoxib in HER2-negative cases did not increase the pCR rate. We report here the long-term follow-up results for disease-free survival (DFS) and overall survival (OS). PATIENTS AND METHODS: From 2004 to 2007, 340 stage II-III BC patients were randomly assigned to receive neoadjuvant EC-T (four cycles of epirubicin-cyclophosphamide followed by four cycles of docetaxel) +/- celecoxib in HER2-negative cases (n = 220) and ± trastuzumab in HER2-positive cases (n = 120)...
March 6, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28275922/scalp-cooling-with-adjuvant-neoadjuvant-chemotherapy-for-breast-cancer-and-the-risk-of-scalp-metastases-systematic-review-and-meta-analysis
#13
REVIEW
Hope S Rugo, Susan A Melin, Jeff Voigt
PURPOSE: The risk of scalp metastases in patients using scalp cooling for preservation of hair during chemotherapy has been a concern but is poorly described. METHODS: A systematic review and meta-analysis of longitudinal studies was undertaken to evaluate the effect of scalp cooling versus no scalp cooling on the risk of scalp metastasis in patients treated for breast cancer with chemotherapy. Electronic databases, journal specific, and hand searches of articles identified were searched...
March 8, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28272005/bilateral-breast-cancer-after-prophylactic-bilateral-pulmonary-irradiation
#14
Hamrouni A El Meddeb, Jebsi M Chehata, S Kanoun, C Rancoule, J B Guy, N Magne, N Bouaouina
The purpose of this article is to report a new case of a probably radio-induced bilateral breast cancer occurred after prophylactic bilateral pulmonary irradiation in the treatment of osteosarcoma. A 42-year-old woman, treated at the age of 12 years for osteosarcoma at the right lower limb with chemotherapy (methotrexate, adriamycin and cisplatin) followed by non-conservative surgery and adjuvant radiotherapy. Eighteen years after, she developed her first breast cancer, and five years later, her second contralateral breast cancer...
January 2017: Gulf Journal of Oncology
https://www.readbyqxmd.com/read/28267750/changes-in-brain-activation-in-breast-cancer-patients-depend-on-cognitive-domain-and-treatment-type
#15
Sanne Menning, Michiel B de Ruiter, Dick J Veltman, Willem Boogerd, Hester S A Oldenburg, Liesbeth Reneman, Sanne B Schagen
BACKGROUND: Cognitive problems in breast cancer patients are common after systemic treatment, particularly chemotherapy. An increasing number of fMRI studies show altered brain activation in breast cancer patients after treatment, suggestive of neurotoxicity. Previous prospective fMRI studies administered a single cognitive task. The current study employed two task paradigms to evaluate whether treatment-induced changes depend on the probed cognitive domain. METHODS: Participants were breast cancer patients scheduled to receive systemic treatment (anthracycline-based chemotherapy +/- endocrine treatment, n = 28), or no systemic treatment (n = 24) and no-cancer controls (n = 31)...
2017: PloS One
https://www.readbyqxmd.com/read/28264824/cost-effectiveness-analysis-of-an-18-week-exercise-programme-for-patients-with-breast-and-colon-cancer-undergoing-adjuvant-chemotherapy-the-randomised-pact-study
#16
Anne M May, Marcel J C Bosch, Miranda J Velthuis, Elsken van der Wall, Charlotte N Steins Bisschop, Maartje Los, Frans Erdkamp, Haiko J Bloemendal, Marnix A J de Roos, Marlies Verhaar, Daan Ten Bokkel Huinink, Petra H M Peeters, G Ardine de Wit
OBJECTIVE: Meta-analyses show that exercise interventions during cancer treatment reduce cancer-related fatigue. However, little is known about the cost-effectiveness of such interventions. Here we aim to assess the cost-effectiveness of the 18-week physical activity during cancer treatment (PACT) intervention for patients with breast and colon cancer. The PACT trial showed beneficial effects for fatigue and physical fitness. DESIGN: Cost-effectiveness analyses with a 9-month time horizon (18 weeks of intervention and 18 weeks of follow-up) within the randomised controlled multicentre PACT study...
March 6, 2017: BMJ Open
https://www.readbyqxmd.com/read/28259217/the-first-case-of-her2-invasive-ductal-carcinoma-arising-from-a-breast-hamartoma-and-literature-review
#17
Lea Baer, Sherise Chantell Rogers, Patricia Farrelly, Carmen Tornos, Keith Sweeney
Carcinomas arising from breast hamartomas are exceedingly rare. We present the first reported case of an African-American female presenting with a right breast lump and a subsequent mammogram suggestive of a hamartoma. She later underwent lumpectomy and was found to have HER2+ invasive ductal carcinoma (IDC) arising from a hamartoma. She was amenable to HER2-targeted trastuzumab, hormone therapy and adjuvant radiation but declined chemotherapy. In a review of the literature, IDC is the predominant neoplastic type found in hamartomas...
April 2017: Journal of the National Medical Association
https://www.readbyqxmd.com/read/28258988/serum-igf-1-igfbp-3-levels-and-circulating-tumor-cells-ctcs-in-early-breast-cancer-patients
#18
Georgios Z Papadakis, Dimitrios Mavroudis, Vasilios Georgoulias, John Souglakos, Athanasios K Alegakis, George Samonis, Ulas Bagci, Antonis Makrigiannakis, Odysseas Zoras
OBJECTIVE: Insulin-like growth factor (IGF)-axis is involved in human oncogenesis and metastasis development for various solid tumors including breast cancer. Aim of this study was to assess the association between IGF-1, IGF-binding protein-3 (IGFBP-3) serum levels and the presence of circulating tumor cells (CTCs) in the peripheral blood of women diagnosed with early breast cancer (EBC), before and after adjuvant chemotherapy. DESIGN: 171 patients with early-stage breast adenocarcinomas were retrospectively evaluated...
February 16, 2017: Growth Hormone & IGF Research
https://www.readbyqxmd.com/read/28258786/treatment-recommendations-for-older-women-with-breast-cancer-a-survey-among-surgical-radiation-and-medical-oncologists
#19
V C Hamelinck, A M Stiggelbout, C J H van de Velde, G-J Liefers, E Bastiaannet
PURPOSE: As older women with breast cancer (BC) are underrepresented in trials, it is often unclear what represents the best treatment option for this patient group. To understand how oncologists approach the management of BC in older patients, we assessed their treatment recommendations. METHODS: In an online survey, 106 surgical, 37 radiation and 31 medical oncologists provided a treatment recommendation for hypothetical patients aged >70 years. Scenarios included loco-regional therapy with patient age varying at 76 and 84 years; systemic therapy with Karnofsky performance score varying at 90 and 50%; neo-adjuvant therapy; and adjuvant chemotherapy in triple-negative BC...
February 20, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28253244/body-mass-index-bmi-association-with-clinicopathological-factors-and-outcome-of-women-with-newly-diagnosed-breast-cancer-in-new-zealand
#20
Bridget Robinson, Margaret Currie, Elisabeth Phillips, Gabi Dachs, Matthew Strother, Helen Morrin, Val Davey, Chris Frampton
AIMS: To identify associations of obesity with breast cancer and its outcome in a New Zealand population, including those treated with adjuvant chemotherapy. METHODS: Data was collated from four regional Breast Cancer Registers, Auckland, Waikato, Wellington and Christchurch, for all women with newly diagnosed breast cancer, with weight and height recorded. Associations of body mass index (BMI) with patient and tumour characteristics, and all-cause mortality were determined...
March 3, 2017: New Zealand Medical Journal
keyword
keyword
31152
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"